These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 26250577)

  • 1. DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype.
    Nangalia J; Nice FL; Wedge DC; Godfrey AL; Grinfeld J; Thakker C; Massie CE; Baxter J; Sewell D; Silber Y; Campbell PJ; Green AR
    Haematologica; 2015 Nov; 100(11):e438-42. PubMed ID: 26250577
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutation analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese patients with myeloproliferative neoplasms.
    Wang M; He N; Tian T; Liu L; Yu S; Ma D
    Biomed Res Int; 2014; 2014():485645. PubMed ID: 24895580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms.
    Abdel-Wahab O; Pardanani A; Rampal R; Lasho TL; Levine RL; Tefferi A
    Leukemia; 2011 Jul; 25(7):1219-20. PubMed ID: 21519343
    [No Abstract]   [Full Text] [Related]  

  • 4. JAK2 haplotype 46/1 and JAK2 V617F allele burden in MPN: New evidence against the "hypermutability" hypothesis?
    Stolyar MA; Klimova OA; Gorbenko AS; Brenner EV; Titov SE; Ivanov MK; Olkhovskiy IA
    Int J Lab Hematol; 2018 Feb; 40(1):e8-e10. PubMed ID: 29134760
    [No Abstract]   [Full Text] [Related]  

  • 5. Alterations to
    Venugopal K; Feng Y; Shabashvili D; Guryanova OA
    Cancer Res; 2021 Jan; 81(2):254-263. PubMed ID: 33087320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.
    Brecqueville M; Rey J; Bertucci F; Coppin E; Finetti P; Carbuccia N; Cervera N; Gelsi-Boyer V; Arnoulet C; Gisserot O; Verrot D; Slama B; Vey N; Mozziconacci MJ; Birnbaum D; Murati A
    Genes Chromosomes Cancer; 2012 Aug; 51(8):743-55. PubMed ID: 22489043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloproliferative neoplasms with a low (<5%) CALR mutation allele burden.
    Lee Tokar L; Crotty G; O'Keeffe D; Langabeer SE
    Blood Cells Mol Dis; 2021 Sep; 90():102593. PubMed ID: 34217938
    [No Abstract]   [Full Text] [Related]  

  • 8. DNMT3A in haematological malignancies.
    Yang L; Rau R; Goodell MA
    Nat Rev Cancer; 2015 Mar; 15(3):152-65. PubMed ID: 25693834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia.
    Ferreira HJ; Heyn H; Vizoso M; Moutinho C; Vidal E; Gomez A; Martínez-Cardús A; Simó-Riudalbas L; Moran S; Jost E; Esteller M
    Oncogene; 2016 Jun; 35(23):3079-82. PubMed ID: 26434589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.
    Courtier F; Carbuccia N; Garnier S; Guille A; Adélaïde J; Cervera N; Gelsi-Boyer V; Mozziconacci MJ; Rey J; Vey N; Chaffanet M; Birnbaum D; Murati A
    Haematologica; 2017 Jan; 102(1):e11-e14. PubMed ID: 27742771
    [No Abstract]   [Full Text] [Related]  

  • 11. Absence of JAK2V617F mutation in Chinese deep vein thrombosis patients without myeloproliferative neoplasms.
    Dong B; Zhang Y; Fu X; Wang G
    Thromb Res; 2012 May; 129(5):664-5. PubMed ID: 22197451
    [No Abstract]   [Full Text] [Related]  

  • 12. The spectrum of DNMT3A variants in Tatton-Brown-Rahman syndrome overlaps with that in hematologic malignancies.
    Shen W; Heeley JM; Carlston CM; Acuna-Hidalgo R; Nillesen WM; Dent KM; Douglas GV; Levine KL; Bayrak-Toydemir P; Marcelis CL; Shinawi M; Carey JC
    Am J Med Genet A; 2017 Nov; 173(11):3022-3028. PubMed ID: 28941052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis.
    Loberg MA; Bell RK; Goodwin LO; Eudy E; Miles LA; SanMiguel JM; Young K; Bergstrom DE; Levine RL; Schneider RK; Trowbridge JJ
    Leukemia; 2019 Jul; 33(7):1635-1649. PubMed ID: 30692594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNMT3A mutations in myeloproliferative neoplasms.
    Stegelmann F; Bullinger L; Schlenk RF; Paschka P; Griesshammer M; Blersch C; Kuhn S; Schauer S; Döhner H; Döhner K
    Leukemia; 2011 Jul; 25(7):1217-9. PubMed ID: 21537334
    [No Abstract]   [Full Text] [Related]  

  • 15. DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia.
    Meyer SE; Qin T; Muench DE; Masuda K; Venkatasubramanian M; Orr E; Suarez L; Gore SD; Delwel R; Paietta E; Tallman MS; Fernandez H; Melnick A; Le Beau MM; Kogan S; Salomonis N; Figueroa ME; Grimes HL
    Cancer Discov; 2016 May; 6(5):501-15. PubMed ID: 27016502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.
    Im AP; Sehgal AR; Carroll MP; Smith BD; Tefferi A; Johnson DE; Boyiadzis M
    Leukemia; 2014 Sep; 28(9):1774-83. PubMed ID: 24699305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focus on the epigenome in the myeloproliferative neoplasms.
    Kim E; Abdel-Wahab O
    Hematology Am Soc Hematol Educ Program; 2013; 2013():538-44. PubMed ID: 24319229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer.
    Epstein-Peterson ZD; Devlin SM; Stein EM; Klimek VM; Saltz LB; Tallman MS
    Leuk Res; 2019 Jul; 82():19-23. PubMed ID: 31151028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis.
    Zhang X; Wang X; Wang XQD; Su J; Putluri N; Zhou T; Qu Y; Jeong M; Guzman A; Rosas C; Huang Y; Sreekumar A; Li W; Goodell MA
    Blood; 2020 Mar; 135(11):845-856. PubMed ID: 31932841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Involvement of aberrant DNA methylation in hematological malignancies].
    Matsui H
    Rinsho Ketsueki; 2014 Oct; 55(10):1709-14. PubMed ID: 25297731
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.